Ann Arbor Stage III Grade 2 Follicular Lymphoma

9 clinical trials · Condition

Record	Firm	Date
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma (NCT05025800)	M.D. Anderson Cancer Center	2021-10-13
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma (NCT04404088)	M.D. Anderson Cancer Center	2020-07-16
Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma (NCT02871219)	M.D. Anderson Cancer Center	2016-12-06
Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma (NCT02494700)	M.D. Anderson Cancer Center	2015-07-06
Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma (NCT01829568)	National Cancer Institute (NCI)	2013-06-26
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma (NCT01286272)	National Cancer Institute (NCI)	2011-04-28
Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma (NCT01145495)	National Cancer Institute (NCI)	2010-06-15
Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma (NCT00695786)	M.D. Anderson Cancer Center	2008-06-10

Every clearance here is in the API, with alerts when new ones post.